Evidence map›Paper›PMID 42568817›Full record

ArticleMedComm2026

A Chemotherapy Progression Decision Score for Treatment Selection After Initial Assessment in Pancreatic Ductal Adenocarcinoma.

Yixin Zhang, Zhongquan Sun, Hongfan Ding, Changlin Zou, Linping Dong, Qi Xu, Jiali Ji, Xin Han, Hanqi Yu, Daqian Xu and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Yixin ZhangDepartment of Hepatobiliary and Pancreatic Surgery The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang China.
Zhongquan SunDepartment of Hepatobiliary and Pancreatic Surgery The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang China.
Hongfan DingDepartment of Hepatobiliary and Pancreatic Surgery The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang China.
Changlin ZouDepartment of Radiotherapy and Chemotherapy The First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang China.
Linping DongDepartment of Hepatobiliary and Pancreatic Surgery The Fourth Affiliated Hospital, Zhejiang University School of Medicine Yiwu Zhejiang China.
Qi XuDepartment of Hepato-Pancreato-Biliary & Gastric Medical Oncology Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences Hangzhou Zhejiang China.
Jiali JiDepartment of Hepatobiliary and Pancreatic Surgery The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang China.
Xin HanDepartment of Hepatobiliary and Pancreatic Surgery The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang China.
Hanqi YuDepartment of Hepatobiliary and Pancreatic Surgery The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang China.
Daqian XuZhejiang Provincial Key Laboratory of Pancreatic Disease The First Affiliated Hospital, Institute of Translational Medicine, Zhejiang University School of Medicine, Zhejiang University Hangzhou China.
Gaopeng LiDepartment of Colorectal Surgery and Oncology of the Second Affiliated Hospital and Institute of Translational Medicine, Zhejiang University School of Medicine Hangzhou China.
Yuhao WangZhejiang Provincial Key Laboratory of Pancreatic Disease The First Affiliated Hospital, Institute of Translational Medicine, Zhejiang University School of Medicine, Zhejiang University Hangzhou China.
Haoliang HeDepartment of Hepatobiliary and Pancreatic Surgery The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang China.
Yufeng ZhongDepartment of Hepatobiliary and Pancreatic Surgery The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang China.
Xiaochang WuDepartment of Hepatobiliary Surgery Huzhou Central Hospital, Zhejiang University Huzhou Hospital Huzhou Zhejiang China.
Jieer YingDepartment of Hepato-Pancreato-Biliary & Gastric Medical Oncology Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences Hangzhou Zhejiang China.
Weilin WangDepartment of Hepatobiliary and Pancreatic Surgery The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang China.ORCID https://orcid.org/0000-0001-9432-2649
Yuan DingDepartment of Hepatobiliary and Pancreatic Surgery The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang China.ORCID https://orcid.org/0000-0002-3840-9886

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with chemotherapy response evaluation currently relying on the Response Evaluation Criteria in Solid Tumors (RECIST). However, RECIST inadequately captures the unique biology of PDAC, particularly stromal fibrosis-induced radiographic pseudoprogression. We developed and externally validated a multivariable prognostic prediction model, the chemotherapy Progression Decision (cPD) score, integrating biological markers and imaging metrics to guide therapeutic decision-making after the first RECIST assessment. This multicenter retrospective study enrolled 616 PDAC patients across three cohorts: the Training Cohort (

Indexed as

chemotherapy responsepancreatic ductal adenocarcinomaprognostic prediction modelradiographic pseudoprogressiontreatment decision‐making

Identifiers

PMID42568817
PMCPMC13448143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.